News
Crystal Pharmatech Launches OEB4/OEB5 High-Potency Laboratory, Expanding Global CDMO Capabilities for Complex Drug Development
02 Apr 2026
Solid-State, Crystallization, and CMC Control for Drug Development – A Crystal Pharmatech Case Study Series
From early developability to late-stage specifications—polymorph/salt-cocrystal strategy, SCXRD/MicroED solutions, solvent & pathway design, drug-product form control, ASD crystalline-form limits...
Subscribe to be the first to get the updates!